ClinicalTrials.gg
RecruitingNCT06226051Updated Nov 5, 2026

Growing Little PEAPODS Study

An observational study in Premature Birth, Premature Infant and Premature, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 22 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Wisconsin, Madison · Observational

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
22 Weeks to 32 Weeks
Sex
All
01

Study summary

The goal of this clinical trial is to learn more about how the food and nutrition babies receive while in the Neonatal Intensive Care Unit (NICU) influences their ability to gain weight and fat-free mass, and their future growth and development.

Participants will:

  • have body growth measurements collected using the PEAPOD device
  • have nutritional information collected, and
  • be followed for neurodevelopmental outcomes

Participants can expect to be in the study for 36 months.

02

Conditions studied

  • Premature Birth
  • Premature Infant
  • Premature
  • Intrauterine Growth Restriction
  • Small for Gestational Age at Delivery
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's planned enrollment of 120 is close to the median of 120 across 806 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,188 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Weeks to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

120 neonates born inpatient at Meriter Hospital, Inc. ≤ 32 weeks 6 days (32w6d) GA (possible gestational age range from 22w0d-32w6d)

Eligibility criteria

Neonate Inclusion Criteria:

  • Born inpatient at Meriter Hospital, Inc. at or above 22 gestational weeks. Upper limit is 32 weeks 6 days GA (possible gestational age range from 22w0d-32w6d)

Neonate Exclusion Criteria:

  • Known genetic condition that impacts neurodevelopmental outcomes or brain structure development
  • Multiple major congenital anomalies
  • Per the investigator's opinion, the subject will likely require transfer to American Family Children's Hospital (AFCH) before 36 weeks PMA

    • Any neonate who enrolls in the study and then unexpectedly requires transfer to AFCH before 36 weeks PMA will be excluded from the study if they are unable to obtain at least one body composition measurement before transfer. Body composition data points can only be collected at Meriter Hospital due to the location of PEAPOD

Birthing Parent Inclusion Criteria:

  • Birthing parent must speak English or Spanish due to consent documents
  • Able to understand and willing to sign a written document
  • Primary caregiver of a neonate who is eligible to participate in the study
  • Agrees to enroll neonate into the study
  • Willing to comply with all study procedures and be available for the duration of the study
  • Age 15 or older

Birthing Parent Exclusion Criteria:

  • Subject is unable to provide informed consent, including subjects in foster care and subjects within state custody
  • Does not plan to maintain custody of the child after birth, such as in instances of adoption or surrogacy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • PEAPOD device

    Premature babies will be evaluated using the PEAPOD Infant Body Composition measuring device

    Device: PEAPOD Infant Body Composition measuring device

Interventions

  • DevicePEAPOD Infant Body Composition measuring device

    PEAPOD is a device to that collects body composition measurements.

06

What researchers measure

Primary outcomes

  1. To evaluate the correlation between nutritional intake over the first two weeks of life and the percent increase in fat-free mass measured by the PEAPOD

    The least absolute shrinkage and selection operator technique will be utilized to determine whether fat intake predicts a percent increase in fat-free mass

    Time frame: Birth to 2 weeks

  2. To evaluate the correlation between higher nutritional intake in the first 2 weeks of life and the General Movement Assessment (GMA) and/or the Bayley Scales of Infant and Toddler Developmental Scores (Bayley)

    The least absolute shrinkage and selection operator technique will be utilized to determine whether higher nutritional intake predicts Bayley cognitive scores

    Time frame: Birth to 36 months

  3. To evaluate the correlation between the percent increase in fat-free mass and the GMA and/or Bayley scores.

    The least absolute shrinkage and selection operator technique will be utilized to determine whether the percent increase in fat-free mass predicts GMA scores and Bayley scores.

    Time frame: Birth to 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jan 2028, 40 months after the start.

Of 372 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 40 months is above that.

Counting every sponsor, half of 387 studies reached it within 35 months; a quarter within 18 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2024
First posted
Jan 26, 2024
StartActual
Sep 4, 2024
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06226051
Collaborators
Meriter Hospital, Inc.
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Sep 4, 2024
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Whitley Hulse, MD
Contact
whulse@wisc.edu
608-620-4924
Whitley Hulse, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion